| Sintilimab studied in …STUDIED_INderived200 of 317show all (up to 200) |
|---|
| → studied in | NCT06618664Phase 3 · recruiting A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02) · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07840677Phase 2 · recruiting Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer · 317 trials list this drug (156 active) | — | — | Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07722754Phase 2 · recruiting Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial · 317 trials list this drug (156 active) | — | — | Neoplasm,Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07831993Phase 2 · recruiting Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer · 317 trials list this drug (156 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07832006Phase 2 · recruiting Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07827872Phase 3 · not yet recruiting Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma · 317 trials list this drug (156 active) | — | — | Oral Cavity Neoplasm,Head and Neck Squamous Cell Carcinoma,Oral Cavity Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06730373Phase 2 · recruiting First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) · 317 trials list this drug (156 active) | — | — | Malignant Gastric Neoplasm,Gastric Carcinoma,HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07061535Phase 2 · recruiting Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer · 317 trials list this drug (156 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07819019Phase 2 · not yet recruiting A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer · 317 trials list this drug (156 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07813572Phase 3 · not yet recruiting ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07400302Phase 2 · recruiting Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery · 317 trials list this drug (156 active) | — | — | Mucosal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07797816Phase 2 · recruiting Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer · 317 trials list this drug (156 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07557251Phase 1 · recruiting A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07025889Phase 1/Phase 2 · recruiting IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer · 317 trials list this drug (156 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07768943Phase 2 · not yet recruiting GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma · 317 trials list this drug (156 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07756190Phase 2 · not yet recruiting Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study · 317 trials list this drug (156 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06447636Phase 2 · active not recruiting Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma · 317 trials list this drug (156 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07748325Phase 2 · recruiting Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07745790Phase 2 · not yet recruiting Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer · 317 trials list this drug (156 active) | — | — | Lung Neoplasm,Liver Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07179900Phase 2 · recruiting Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07740993Phase 2 · not yet recruiting A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma · 317 trials list this drug (156 active) | — | — | Sebaceous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07738042NA · not yet recruiting To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMR · 317 trials list this drug (156 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05621499NA · active not recruiting HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05026736Phase 2 · terminated Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study · 317 trials list this drug (156 active) | — | — | Angiosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07715565Phase 2 · not yet recruiting Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial · 317 trials list this drug (156 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07699757Phase 1 · not yet recruiting HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion · 317 trials list this drug (156 active) | — | — | Solid Neoplasm,Lung Non-Small Cell Carcinoma,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07692152Phase 3 · recruiting Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma · 317 trials list this drug (156 active) | — | — | Anal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07686796Phase 3 · not yet recruiting Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07656766Phase 2 · not yet recruiting Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer · 317 trials list this drug (156 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07670026Phase 2 · recruiting Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression · 317 trials list this drug (156 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638631Phase 2 · not yet recruiting Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer · 317 trials list this drug (156 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05890742Phase 3 · active not recruiting A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07612137Phase 1/Phase 2 · not yet recruiting Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors · 317 trials list this drug (156 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07594925Phase 2 · recruiting Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial · 317 trials list this drug (156 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07394387Phase 2 · recruiting Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer. · 317 trials list this drug (156 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07584018Phase 2 · not yet recruiting The DoHAICs Study Expansion Phase · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03607539Phase 3 · completed Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC · 317 trials list this drug (156 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06431685Phase 1 · recruiting Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma,Meningeal Carcinomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07574528Phase 2 · not yet recruiting A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05201859Phase 2 · active not recruiting Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma · 317 trials list this drug (156 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07560488Phase 2 · recruiting Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05357846Phase 3 · recruiting PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101) · 317 trials list this drug (156 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07309952Phase 2 · recruiting Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06204094Phase 2 · recruiting Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer · 317 trials list this drug (156 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03872661Phase 2 · recruiting Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC · 317 trials list this drug (156 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06860490Phase 2 · recruiting HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03) · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07147101recruiting Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07535632Phase 2 · not yet recruiting SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer · 317 trials list this drug (156 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07537946Phase 3 · not yet recruiting Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07537972Phase 2 · not yet recruiting Denosumab Strategy for Liver Cancer With Bone Metastases · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07490262Phase 2/Phase 3 · recruiting A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07518602Phase 2 · recruiting Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma · 317 trials list this drug (156 active) | — | — | Extrapulmonary Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07506109Phase 2 · recruiting A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer · 317 trials list this drug (156 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07515625Phase 2 · not yet recruiting Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma · 317 trials list this drug (156 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07455617Phase 1 · recruiting Study of ABO2102 in KRAS-Mutated Solid Tumors · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04877821Phase 2 · completed The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC · 317 trials list this drug (156 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07487662Phase 2 · not yet recruiting TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05427487Phase 1 · recruiting Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours · 317 trials list this drug (156 active) | — | — | Malignant Gastric Neoplasm,Malignant Ovarian Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07457281Phase 1 · recruiting GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07492615Phase 2 · recruiting A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma · 317 trials list this drug (156 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04720716Phase 3 · completed A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06497985Phase 3 · recruiting A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients · 317 trials list this drug (156 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07459296Phase 3 · recruiting Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC · 317 trials list this drug (156 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07474103NA · recruiting SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC · 317 trials list this drug (156 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07468630Phase 2 · recruiting Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · 317 trials list this drug (156 active) | — | — | Colon Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06530251Phase 1/Phase 2 · recruiting A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05024968Phase 2 · completed Sintilimab in Cancer of Unknown Primary · 317 trials list this drug (156 active) | — | — | Malignant Neoplasm of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05171660Phase 3 · active not recruiting Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer · 317 trials list this drug (156 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06353646NA · recruiting XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer · 317 trials list this drug (156 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07005336Phase 2 · active not recruiting A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07077512Phase 2 · recruiting Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma · 317 trials list this drug (156 active) | — | — | Follicular Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07352007Phase 2 · not yet recruiting Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07120698Phase 2 · recruiting Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07306663Phase 3 · active not recruiting Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study · 317 trials list this drug (156 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05472948Phase 2 · recruiting Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma · 317 trials list this drug (156 active) | — | — | Appendix Neoplasm,Appendix Carcinoma,Small Intestinal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06121505Phase 2 · recruiting Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer · 317 trials list this drug (156 active) | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07263386Phase 2 · recruiting A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer · 317 trials list this drug (156 active) | — | — | Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07157969Phase 2 · recruiting ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06220318Phase 1/Phase 2 · active not recruiting Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors · 317 trials list this drug (156 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05383482Phase 1/Phase 2 · completed Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 · 317 trials list this drug (156 active) | — | — | Solid Neoplasm,Malignant Esophageal Neoplasm,Lung Non-Small Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07194005Phase 2 · recruiting Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer · 317 trials list this drug (156 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07088731Phase 2 · not yet recruiting Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer · 317 trials list this drug (156 active) | — | — | Cervical Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07186621Phase 3 · recruiting Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06512207NA · recruiting A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05481476Phase 2 · active not recruiting Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer · 317 trials list this drug (156 active) | — | — | Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06323382recruiting Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04961515Phase 2 · recruiting Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma · 317 trials list this drug (156 active) | — | — | Primary Central Nervous System Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06031285Phase 2 · recruiting Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07077798NA · not yet recruiting Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07053150Phase 2 · not yet recruiting A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors · 317 trials list this drug (156 active) | — | — | Digestive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05116462Phase 3 · active not recruiting Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07040098Phase 2 · recruiting Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer · 317 trials list this drug (156 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05161572Phase 2 · terminated Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer · 317 trials list this drug (156 active) | — | — | Gastric Neoplasm,Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06013618Phase 2 · recruiting Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma · 317 trials list this drug (156 active) | — | — | Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04548440Phase 2 · completed Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients · 317 trials list this drug (156 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07018063Phase 2 · not yet recruiting Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer · 317 trials list this drug (156 active) | — | — | Gastric Neoplasm,Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07010393Phase 4 · not yet recruiting Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study · 317 trials list this drug (156 active) | — | — | Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07007767Phase 2 · not yet recruiting Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies） · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06956716Phase 1/Phase 2 · recruiting Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma · 317 trials list this drug (156 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06900218Phase 3 · not yet recruiting PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma · 317 trials list this drug (156 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06904014Phase 2 · recruiting Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06888648Phase 1/Phase 2 · not yet recruiting Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer. · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06888674Phase 1/Phase 2 · not yet recruiting Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer. · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05165407Phase 2 · recruiting Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE) · 317 trials list this drug (156 active) | — | — | Neuroendocrine Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04836728Phase 2 · active not recruiting Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06698757Phase 2 · recruiting Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer · 317 trials list this drug (156 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03812549Phase 1 · completed Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04297280Phase 2 · completed TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05010681Phase 2 · recruiting Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer · 317 trials list this drug (156 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05057052Phase 2 · recruiting Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05098847Phase 2 · recruiting Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06494943Phase 1/Phase 2 · recruiting Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC · 317 trials list this drug (156 active) | — | — | Malignant Head and Neck Neoplasm,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06841159Phase 2 · recruiting Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05010668Phase 2 · completed Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma · 317 trials list this drug (156 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06837948Phase 2 · not yet recruiting Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04423185Phase 2 · recruiting PLATFORM Study of Precision Medicine for Rare Tumors · 317 trials list this drug (156 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06333561recruiting HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05504278Phase 1 · recruiting Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06788171Phase 2 · not yet recruiting PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05562297Phase 2 · not yet recruiting Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer · 317 trials list this drug (156 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06572813Phase 1/Phase 2 · recruiting Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer · 317 trials list this drug (156 active) | — | — | Pancreatic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06584032Phase 3 · recruiting Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer · 317 trials list this drug (156 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06761911Phase 4 · not yet recruiting BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma · 317 trials list this drug (156 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06558227Phase 2 · recruiting Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05017103Phase 2 · terminated Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study · 317 trials list this drug (156 active) | — | — | Undifferentiated Pleomorphic Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04212598Phase 2 · completed The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer · 317 trials list this drug (156 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06718205Phase 2 · recruiting Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma · 317 trials list this drug (156 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04940546Phase 1/Phase 2 · active not recruiting Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06709417Phase 2 · recruiting A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS) · 317 trials list this drug (156 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06685276Phase 2 · recruiting Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06697366Phase 2 · not yet recruiting Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer · 317 trials list this drug (156 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04973293NA · recruiting Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05979818Phase 1 · recruiting Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04258111Phase 2 · terminated IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer · 317 trials list this drug (156 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06313190Phase 2 · recruiting Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402) · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06692491Phase 2 · not yet recruiting Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · 317 trials list this drug (156 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06688656Phase 2 · not yet recruiting Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC · 317 trials list this drug (156 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06680115Phase 2 · not yet recruiting Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma · 317 trials list this drug (156 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04954794Phase 2 · completed TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02) · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06664996Phase 2 · recruiting Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06652412Phase 2 · not yet recruiting CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC · 317 trials list this drug (156 active) | — | — | Malignant Colon Neoplasm,Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05495152Phase 3 · recruiting Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma · 317 trials list this drug (156 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06620822Phase 2 · not yet recruiting Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04167657Phase 2 · completed SinTilimab After Radiation (STAR Study) · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04401813Phase 1 · completed Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05625737Phase 2 · unknown Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma · 317 trials list this drug (156 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06564298Phase 2 · unknown A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis · 317 trials list this drug (156 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06555471Phase 2 · recruiting A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer · 317 trials list this drug (156 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04735861Phase 2 · completed Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06070636NA · unknown bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06543836Phase 2 · unknown ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer · 317 trials list this drug (156 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04636008Phase 1/Phase 2 · unknown Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer · 317 trials list this drug (156 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04220944Phase 1 · unknown Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06523049Phase 2 · not yet recruiting Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy · 317 trials list this drug (156 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06512467Phase 2 · not yet recruiting Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06413342Phase 2 · recruiting Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma · 317 trials list this drug (156 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03989336Phase 2 · completed A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer · 317 trials list this drug (156 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05244213Phase 2 · unknown Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06487715Phase 2 · unknown Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06475196unknown Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC · 317 trials list this drug (156 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06463834Phase 2 · recruiting A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma · 317 trials list this drug (156 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06461936unknown Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04842565Phase 2 · completed cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06421298Phase 2 · recruiting A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy. · 317 trials list this drug (156 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06403878Phase 2 · unknown Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer · 317 trials list this drug (156 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05804526Phase 1/Phase 2 · unknown A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours · 317 trials list this drug (156 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06089369Phase 3 · not yet recruiting Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06347198early Phase 1 · unknown Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer · 317 trials list this drug (156 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06341595Phase 2 · recruiting Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM · 317 trials list this drug (156 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05098119Phase 2 · recruiting Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) · 317 trials list this drug (156 active) | — | — | Oral Cavity Squamous Cell Carcinoma,Oropharyngeal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06308939Phase 2 · unknown Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial · 317 trials list this drug (156 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05004974Phase 2 · unknown Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04618367NA · completed HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT · 317 trials list this drug (156 active) | — | — | Liver Neoplasm,Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04627012completed Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06285019Phase 2 · unknown Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06240689Phase 2 · recruiting A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood · 317 trials list this drug (156 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04326153Phase 2 · active not recruiting Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06221462Phase 2 · not yet recruiting Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06220552Phase 2 · recruiting The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma · 317 trials list this drug (156 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05088967Phase 1 · terminated Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06198907Phase 2 · not yet recruiting Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06190639Phase 2 · recruiting A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC · 317 trials list this drug (156 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04590599Phase 2 · completed A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy · 317 trials list this drug (156 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06161909Phase 3 · unknown Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06152978Phase 2 · not yet recruiting A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma · 317 trials list this drug (156 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03802240Phase 3 · completed Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure · 317 trials list this drug (156 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04906044Phase 1 · unknown Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer · 317 trials list this drug (156 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06123455Phase 2 · unknown Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer · 317 trials list this drug (156 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03748134Phase 3 · completed Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) · 317 trials list this drug (156 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06089382Phase 3 · not yet recruiting A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05250843Phase 2/Phase 3 · unknown TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05450029Phase 2 · recruiting Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer · 317 trials list this drug (156 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04728724Phase 2 · recruiting Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer · 317 trials list this drug (156 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06029829Phase 2 · unknown The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution. · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05795296Phase 2 · unknown Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer · 317 trials list this drug (156 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05839275Phase 1/Phase 2 · recruiting The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05976568Phase 2/Phase 3 · not yet recruiting A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05971199Phase 2 · unknown Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma · 317 trials list this drug (156 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04724239Phase 2 · unknown Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma · 317 trials list this drug (156 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05026593Phase 1 · completed A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer · 317 trials list this drug (156 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |